8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 7, 2006

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	1-10730	04-2882273
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

400 Wood Road	02184
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code   781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 OTHER EVENTS

On June 6, 2006 we entered into a definitive agreement with Arryx, Inc. (Arryx), a privately held nano-technology company, whereby we will acquire the outstanding shares of Arryx that we do not already own for $26 million in cash.  We have been collaborating with Arryx since October 2004 in developing and commercializing proprietary blood separation and processing technologies.

Item 9.01	FINANCIAL STATEMENTS AND EXHIBITS
(d)	Exhibits.

EXHIBIT 99.1 Press Release of Haemonetics Corporation dated June 8, 2006 announcing the acquisition of Arryx, Inc.

2

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION
	(Registrant)
Date:  June 8, 2006	/s/ Ronald J. Ryan
	Ronald J. Ryan, Vice President and Chief Financial Officer

3

EX-99.1

Exhibit 99.1

99.1     Press Release issued by Haemonetics Corporation on June 8, 2006.

HAEMONETICS CORPORATION Ÿ 400 Wood Road, Braintree, Massachusetts 02184 USA Ÿ (781) 848-7100 Ÿ http://www.haemonetics.com

FOR RELEASE:	CONTACT:
Date:   June 8. 2006	Julie Fallon
Time:  7:00 AM Eastern	Tel. (781) 356-9517
	Alternate Tel. (617) 320-2401
	fallon@haemonetics.com

HAEMONETICS TO ACQUIRE ARRYX IN $26 MILLION TRANSACTION
--Acquisition Will Strengthen and Diversify Haemonetics’ Research Initiatives--

BRAINTREE, MA, DATE – Haemonetics Corporation (NYSE: HAE) and Arryx, Inc., a privately held nano-technology  company, today announced that they have signed a definitive agreement whereby Haemonetics will acquire the outstanding shares of Arryx that it does not already own for $26 million in cash.  Haemonetics and Arryx have been collaborating since October 2004 in developing and commercializing proprietary blood separation and processing technologies.

Arryx’s proprietary technology uses light to form optical traps to move and manipulate small objects.  Using laser beams and holograms, the systems can independently and in parallel hold, move, separate, and otherwise manipulate hundreds of microscopic and nanoscopic objects.  Arryx’s first product, the BioRyx 200^® system, is used to handle cells and other objects in a laboratory environment.

“The acquisition of Arryx is a key component of our strategy to strengthen and diversify our own research initiatives and expand the business by leveraging our core competencies,” said Brad Nutter, Haemonetics’ President and CEO.  “Nano-separation technology adds to our blood separation competency and provides us with a new technology platform.  With Arryx technology and its world class research employees we can see opportunities to broaden our reach into new, adjacent markets.”

Dr. Kenneth Bradley, Arryx’s CEO, said, “Haemonetics’ global resources and commitment to developing innovative healthcare technologies make them an ideal partner for us.  Working together we can more quickly deliver advanced technology platforms.  We look forward to joining Haemonetics.”

The transaction is expected to close in the third quarter of calendar year 2006 and is subject to satisfaction of customary closing conditions.  Arryx’s personnel and operations will remain in Chicago.

Haemonetics expects an additional $0.08 - $0.10 of earnings per share dilution associated with operating expenses and amortization in fiscal 2007.  The Company’s new pro-forma earnings per share guidance is $2.05 to $2.17.  Haemonetics will post a fiscal 2007 guidance scenario on its website.  Additionally, as a result of the transaction, Haemonetics expects to record a one time charge, principally for in-process research and development, which is subject to final independent valuation,

CONFERENCE CALL

Haemonetics will hold a conference call on Thursday, June 8^th at 9:00 am eastern to review the acquisition in more detail.  Interested parties can participate in the conference call by dialing (888) 424-6234 (US only) or (973) 321-1020 with conference ID 7482193.  The call will be replayed through June 22^nd at (877) 519-4471 (US only) or (973) 341-3080 using PIN 7482193.

Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems.  These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety.  To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company’s filings with the Securities and Exchange Commission.  The foregoing list should not be construed as exhaustive.  The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. 

Haemonetics is a registered trademark of Haemonetics Corporation.  Arryx and BioRyx 200 are registered trademarks of Arryx, Inc.

###